EUCTR2005-001457-16-IT进行中（未招募）不适用
RANDOMIZED, DOUBLE BLIND TRIAL MONTELUKAST VERSUS LEVOCETIRIZINE IN THE TREATMENT OF SEASONAL RHINITIS AND CONJUNCTIVITIS IN CHILDREN 6-14 YEARS OLD
IVERSITA' DEGLI STUDI DI UDINE0 个研究点开始时间: 2005年7月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
招募中
2 期
PIIb study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects undergoing Hip Replacement Surgery.CTRI/2009/091/000651Astellas Pharma Inc.
进行中（未招募）
1 期
A Phase 2, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of belimumab and rituximab co-administration in subjects with primary Sjögren’s syndromePrimary Sjogrens diseaseMedDRA version: 20.0Level: PTClassification code 10061664Term: Autoimmune disorderSystem Organ Class: 10021428 - Immune system disordersEUCTR2015-000400-26-DEGlaxoSmithKline R&D Ltd120
进行中（未招募）
1 期
A Phase 2, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of belimumab and rituximab co-administration in subjects with primary Sjögren’s syndromePrimary Sjogrens diseaseMedDRA version: 19.0Level: PTClassification code 10061664Term: Autoimmune disorderSystem Organ Class: 10021428 - Immune system disordersEUCTR2015-000400-26-GBGlaxoSmithKline R&D Ltd120
进行中（未招募）
1 期
A Phase 2, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of belimumab and rituximab co-administration in subjects with primary Sjögren’s syndromePrimary Sjogrens diseaseMedDRA version: 20.0Level: PTClassification code 10061664Term: Autoimmune disorderSystem Organ Class: 10021428 - Immune system disordersEUCTR2015-000400-26-SEGlaxoSmithKline R&D Ltd120
进行中（未招募）
1 期
A Phase 2, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of belimumab and rituximab co-administration in subjects with primary Sjögren's syndromePrimary Sjogrens diseaseMedDRA version: 20.0Level: PTClassification code 10061664Term: Autoimmune disorderSystem Organ Class: 10021428 - Immune system disordersEUCTR2015-000400-26-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT120